EU drugs regulator starts rolling review of Chinese Sinovac vaccine

EMA’s human medicines committee (CHMP) announced on Tuesday that has started a rolling review of COVID-19 Vaccine (Vero Cell) Inactivated, developed by Chinese Sinovac Life Sciences Co., Ltd. The EU applicant for this medicine is Life'On S.r.l. 

The CHMP’s decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and clinical studies. These studies suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease.

EU drugs regulator will evaluate data as they become available to decide if the benefits outweigh the risks. The rolling review will continue until enough evidence is available for a formal marketing authorisation application.

EMA will assess the compliance of COVID-19 Vaccine (Vero Cell) Inactivated with the usual EU standards for effectiveness, safety and quality. While EMA cannot predict the overall timelines, it should take less time than normal to evaluate an eventual application because of the work done during the rolling review.

The agency will communicate further when the marketing authorisation application for the vaccine has been submitted.

COVID-19 Vaccine (Vero Cell) Inactivated is expected to prepare the body to defend itself against infection with SARS-CoV-2. The vaccine contains SARS-CoV-2 that has been inactivated (killed) and cannot cause the disease. COVID-19 Vaccine (Vero Cell) Inactivated also contains an ‘adjuvant’, a substance that helps strengthen the immune response to the vaccine.

When a person is given the vaccine, their immune system identifies the inactivated virus as foreign and makes antibodies against it. If, later, the vaccinated person comes into contact with SARS-CoV-2, the immune system will recognise the virus and be ready to defend the body against it.

Similar articles

  • EU puts off new contract with AstraZeneca

    EU puts off new contract with AstraZeneca

    EU has not yet made any orders for additional Covid-19 jabs from AstraZeneca and talks related to a new contract have stalled, Reuters reported. Internal Market Commissioner Thierry Breton confirmed that at this stage no additional vaccines from this producer are expected beyond June when the current contract expires. Breton also noted that EU will pay higher price for the new version of the Pfizer-BioNTech vaccine.

    33
  • EU buys 1.8bn Pfizer-BioNTech Covid-19 vaccines

    EU buys 1.8bn Pfizer-BioNTech Covid-19 vaccines

    EU announced a contract related to the purchase of a huge amount of Covid-19 jabs, produced by Pfizer-BioNTech, AP reported. The President of the European Commission Ursula von der Leyen posted a message on Twitter saying her office “has just approved a contract for a guaranteed 900 million doses” with the same amount of doses as a future option through 2023.

    76